Table 1 Authoritative recommendations regarding primaquine for the prevention and treatment of P. vivax malaria
From: Management of Plasmodium vivax risk and illness in travelers
| United States | United Kingdom | Canada | International | ||
|---|---|---|---|---|---|
| Source | U.S. government | The Medical Letter | U.K. government | Canadian government | World Health Organization |
| Primaquine as Primary Prophylaxis |
As an alternative to suppressive options or: With travel where malaria is primarily P. vivax Short-term travel Short-notice travel | Only as an alternative to suppressive options | Not recommended | Only as an alternative to suppressive options | None specified except for special risk groups (infants, pregnant women, vulnerable children in seasonal high transmission) |
| Primaquine following a diagnosis of P. vivax | Recommended | Recommended | Recommended | Recommended | Strongly recommended |
| Primaquine following suppressive prophylaxis | Recommended | No recommendation | Not recommended | Recommended for high risk groups | No recommendation |
| References | [21] | [22, 23] | [24, 25] | [26] | [27] |